The pilot study on development of lamivudine-resistance oligonucleotide microarray and its reliability in clinical application
- VernacularTitle:检测拉米夫定耐药位点基因芯片的研制及其应用初探
- Author:
Jiawu SONG
;
Jusheng LIN
;
Xinjuan KONG
;
Kuohuan LIANG
- Publication Type:Journal Article
- Keywords:
DNA mutantional;
Hepatitis B viru;
Microarray;
Drug resistance
- From:
Chinese Journal of Laboratory Medicine
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the development a clinical useful microarray which can detect 4 most commonly and well documented sites for detection of lamivudine-resistance mutants in HBV lamivudine therapy. Methods (1) The selected 16 oligonucleotide probes to screen 4 mutated sites in YMDD region are immoblized in a specific treatment slice by GMS 417 Arrayer. The target 308 bp nucleic acids segment of HBV were amplificated and labeled with Cy5-dCTP fluorescent dye by PCR. After hybridization of target DNA with microarray, the microchips were scanned with Gene TAC LS IV scanner and the data were obtained after processed in computer. (2) To evaluated the specialty and reproducibility of the microarray, the plasmid with Leu515Met, Met539Ile, Met539Val,V542I mutations were condstructed and serve as positive sample. Another 50 sera of lamivudine treated Hepatitis B patients for 6 to 12 months as well as 50 sera without lamivudine administration were assayed by this microarray to evaluated the rate and genetype in lamivudine related resistance mutation. Results The microarray can identify a single base change of selected lamivudine resistance-related mutation and multiple mutation detection by a single assay as well. The specialty are well in agreement with sequencing for 98%. The reproducibility rate of repeat examination is range from 96%-100%. Conclusion The microarray of lamivuine resistance related mutation can identify a single base change as multiple mutations well. And its hight reproducible results may be useful for clinical monitoring lamivudine resistance related HBV mutation.
